BioSpace News Archive

The Lupus Foundation of America will be presenting on the feasibility and acceptability of their new self-management resource, Take Charge, and its study on global recommendations to address major challenges in lupus as part of its Addressing Lupus Pillars for Health Advancement Project, at the American College of Rheumatology’s Convergence annual meeting, taking place November 5-9.

Over 34 million Americans live with diabetes, including over seven million who are undiagnosed.

X4 Pharmaceuticals, Inc. announced that, on October 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the formation of a Scientific Advisory Board (“SAB”), including Karen Ferrante, MD, Gordon Freeman, PhD, Tom Reynolds, MD, PhD, Steven Rosen, MD, and Jeff Settleman, PhD.

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton, Executive Vice President and Chief Financial Officer will present at the following virtual conferences:

Scholar Rock Holding Corporation announced the closing of its underwritten public offering of 3,717,948 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,179,487 shares of its common stock at an exercise price of $0.0001 per share.

Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced topline data from the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES)

Bruker Corporation announced financial results for its third quarter and for the nine months ended September 30, 2020.

Owens & Minor, Inc. reported financial results for the third quarter of 2020, as summarized in the table below.

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in November